Statin therapy is the cornerstone of pharmacologic treatment for patients with elevated low-density lipoprotein cholesterol, yet not all patients achieve individualized treatment goals. Primary care physician John Anderson, MD, and cardiologist/lipidologist Seth Martin, MD, discuss common clinical issues in managing patients with complex and challenging dyslipidemia, including elevated lipoprotein (a) (Lp(a)). They highlight key information from recent cholesterol guidelines, including screening and atherosclerotic cardiovascular disease (ASCVD) risk categorization, as well as recommended goals for high-risk primary prevention patients and those with recurrent ASCVD. Drs. Anderson and Martin discuss the roles, benefits, and limitations of pharmacologic treatment options, and strategies to address barriers to nonstatin lipid-lowering therapies. The 0.75-hour activity promotes critical thinking and application of key concepts to patient cases, enabling participants to advance the care they provide to patients with dyslipidemia.
Course Credit:
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
0.50 Pharmacology Hours
Dates:
Opens: 2025-02-28
Closes: 2026-02-28
Target Audience:
This activity is intended for cardiologists, lipidologists, internal medicine specialists, primary care physicians, nurse practitioners, physician associates, and other clinicians managing patients with dyslipidemia.
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 ANCC contact hours, including 0.5 pharmacology hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
James Backes, PharmD (Medical Writer)No significant relationships to disclose.
Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, Tennessee -
Seth S. Martin, MD
Director of the Advanced Lipid Disorders Program and Digital Health Lab
Ciccarone Center for the Prevention of Cardiovascular Disease
Professor of Medicine
Johns Hopkins
Baltimore, Maryland
Presenting Faculty
Downloads
Learning Objectives
- Categorize individual patients using clinical factors and validated risk assessment tools.
- Recognize the role of Lp(a) in atherosclerotic cardiovascular disease and the appropriate clinical management.
- Identify lipid thresholds to initiate nonstatin therapy and achieve cholesterol targets.
- Implement strategies to overcome clinician and patient barriers to initiating and maintaining nonstatin therapies.
Faculty Disclosures
John E. Anderson, MD
Advisory Board: Abbott, Bayer, Corcept, Eli Lilly, Novo Nordisk, Sanofi
Seth S. Martin, MD
Advisory Board: Care Access
Consultant: Amgen, Arrowhead, HeartFlow, Merck, New Amsterdam, Novartis, Verve Therapeutics